No Competitors and Huge Demand Put BeesFree in a Class by Itself

Over the last 13 years, we have written on and covered thousands of companies that possess important technologies.  Some have helped revolutionize industries and others in the medical space have helped save lives.  As relevant as many of those companies’ offerings were, the technology of BeesFree, Inc. (OTCBB: BEES) just may be one of the most critical to life on Earth that we have ever focused upon.  Bees are a crucial component of our environment and, while many people may only think of them as the little stingers that can be a nuisance, they literally breathe life into the global ecosystem.  Their pollinating efforts are the foundation of the vast majority of the agriculture industry and responsible for $15 billion in added crop value, particularly for specialty crops such as almonds and other nuts, berries, fruits, and vegetables.  Unfortunately, their existence and all that depends upon it, is in jeopardy as a result of an unexplained phenomenon known as Colony Collapse Disorder, or CCD.

No one can exactly pin-down the reason why very socially-oriented adult bees are disappearing from the hive; leaving behind the queen and immature brood with no one to tend to them and simply vanishing.  CCD has been running rampant for nearly six years now with reports from several continents, including North America, registering losses in bee colonies that tally between 30 and 90 percent.  Regarded as “a most important” species on the planet, something has got to be done to put an end to CCD, a disorder more threatening to mankind than the most serious forms of cancer and heart diseases combined.

The good news is that governments have taken action and are spending millions to try and understand and prevent CCD and BeesFree has developed technologies and products that are now being commercialized to help save the global bee population.  BeesFree has incorporated decades of experience from experts in the beekeeping, zoology and microbiology sciences to develop a patent-pending formula and comprehensive CCD preventative (and possibly eradicative) system.  Focused on the strengthening bees’ immune systems and targeting several of the potential culprits underlying CCD, the revolutionary technology utilizes a chemical compound containing natural elements extracted from pure vegetable sources to combat parasites and chemicals in pesticides while also providing nutrients to the bees.

The formulation will only work if the bees ingest it, which is why BeesFree scientists have developed the “Beespenser,” a fully-automated system that naturally attracts bees and gives them a perfect environment for eating and drinking the special, life-saving formula.

BeesFree’s patent-pending formula and delivery system are presently the only integrated solution available to combat the known effects of CCD in a global market whose size measures between $2 and $3 billion.  Given the criticalness of the CCD situation, it would not be a stretch to foresee the products being a raging success as there is simply nothing else out there like it.  Shortly after patent protection documentation was filed in Argentina by BeesFree, the first order followed.  The initial order was valued at $100,000.  Argentina is acutely interested in the technology with their National Institute of Agricultural Technology, a government agency that looks after sustainability in all agricultural businesses and segments, conducting an extensive study on hundreds of beehives to test the effectiveness of the BeesFree’s patent-pending technology in Argentine climates.

BeesFree’s has now filed for protection of its Intellectual Property via the WIPO (World Intellectual Property Organization) which will protect its technologies across the more than 140 countries/states belong to the Patent Cooperation Treaty.

The potential magnitude of uses for BeesFree products could simply mushroom its market cap – which currently stands at only $37.14 million – as commercialization is escalated and word of its effectiveness resonates across the globe.  While the new products of some companies can struggle to gain market share in competitive industries, BeesFree’s products are simply too important to overlook and have no competition, putting this junior firm in a very enviable position with an unprecedented upside.  Proper due diligence of the company and CCD is, as always, encouraged.

Article originally posted on

BeesFree (BEES) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Dig-It Underground Stock Chart Analysis Video

Dig-It Underground Stock Chart Analysis Video(0)

A spike in volume and rise in share price has Dig-It Underground (Pink Sheets: DIGX) on the radar for more movement in the morning. A thinly-traded stock, volatility has been strong in the chart as the MACD trends upwards towards zero as the chart is making a bounce off the bottom. The Relative Strength Index

GelTech Receives First Order for FireIce from Turkey

GelTech Receives First Order for FireIce from Turkey(0)

GelTech Solutions, Inc. (OTCBB: GLTC) this morning reported receipt of the first order from Turkey through partner Nano Girisim Ltd. Sti.  Nano Girism Ltd. Sti., a distributor of industrial products based in Istanbul.  Nano Girisim intends to initially promote GelTech’s FireIce, a revolutionary water enhancing fire suppressant for use in fire extinguishers, as Turkish law

Lyris to Host Third Quarter Earnings Webcast

Lyris to Host Third Quarter Earnings Webcast(0)

Global digital marketing company Lyris, Inc. (OTCBB:LYRI) will report its operating results for the third quarter of fiscal 2012 on Thursday, May 10. The company will hold a conference call and webcast to discuss its financial results and operating activities open to all interested parties at 8 a.m., Pacific Daylight Time (11 a.m., Eastern Daylight

Athersys Meets with FDA to Discuss Suppressing GvHD in Leukemia and other Cancers

Athersys Meets with FDA to Discuss Suppressing GvHD in Leukemia and other Cancers(0)

Graft versus Host Disease (GvHD) is an area of great unmet medical that represents a significant risk to cancer patients throughout the world.  The condition occurs when patients receive a bone marrow transplant following radiation and/or chemotherapy, and the transplanted immune cells begin to attack the patient, causing significant pain and disability, or even death.

Judge Denies Taylor Armstrong’s Request to Dismiss Case with, Damages Could Grow in Excess of $3 Million

Judge Denies Taylor Armstrong’s Request to Dismiss Case with, Damages Could Grow in Excess of $3 Million(0)

In the latest round of the litigation between MMRGlobal, Inc. (OTCBB: MMRF) company (“MMR”) and Beverly Hills Housewife Taylor Armstrong, Los Angeles Superior Court Judge Frederick Shaller dealt a blow to Taylor Armstrong in denying her motion for a summary judgment to have the lawsuit against her dismissed. We first broke the story

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.